Compare JBS N.V. Class A Common Shares (JBS) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JBS N.V. Class A Common Shares vs Johnson & Johnson — how do they compare? JBS N.V. Class A Common Shares trades at $13.02 (market cap $13.96B), while Johnson & Johnson trades at $257.6 (market cap $611.90B). The key difference: Johnson & Johnson is far larger — about 43.8× JBS N.V. Class A Common Shares's market cap, and JBS N.V. Class A Common Shares pays the higher dividend (10.31%). Which is the better fit depends on your goals — on Pluang, investors hold JBS N.V. Class A Common Shares for 0 Days and Johnson & Johnson for 129 Days on average.
| JBS | JNJ | |
|---|---|---|
Market Cap | $13.96B | $611.90B |
Volume | 5,326,589 | 9,651,904 |
Sector | Consumer Staples | Health |
52-Week High | $18.42 | $278.43 |
52-Week Low | $10.86 | $186.00 |
Typical Hold Time | 0 Days | 129 Days |
Enterprise Value | $34.93B | $640.18B |
Dividend Yield | 10.31% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBS trades at $12.93, up 0.54% today, with a neutral technical signal and strong analyst buy consensus. The stock shows attractive valuation with a P/E of 12.08 and P/S of 0.47, though recent quarterly EPS misses and a declining profit margin to 1.22% in 2026 highlight earnings pressure. Recent news includes a proposal to acquire full control of Pilgrim's Pride and a joint venture in Southeast Asia, indicating strategic expansion.
The outlook is mixed: analyst targets suggest ~40% upside to $18.17, but risks include execution on acquisitions, margin compression, and volatile beef markets. Cash flow turned positive in 2026 projections, supporting growth initiatives, yet debt levels and competitive pressures warrant caution for investors seeking stability.
Johnson & Johnson (JNJ) trades at $248.61, down 5.73% over 24 hours, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 67.91% gross margins and 21.48% net income margin, though valuation ratios appear elevated with a P/E of 38.59. Recent earnings show consistent beats except for Q4 2025, with Q3 2026 EPS of $2.59 exceeding expectations. Analyst consensus remains positive with a $282.53 price target, representing 13.6% upside potential from current levels.
JNJ's diversified healthcare portfolio and robust dividend history provide stability, while innovation in pharmaceuticals and medical technology drives growth. Key risks include patent expirations, regulatory challenges, and increasing debt levels. The stock offers defensive characteristics with upside potential from pipeline developments, though current valuation requires careful monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JBS N.V. Class A Common Shares
JBS N.V. is a protein-processing company producing beef, pork, poultry, lamb, fish, and plant-based products, headquartered in São Paulo and Amsterdam. It operates more than 250 production facilities across over 16 countries under brands including Friboi, Seara, Swift, and Pilgrim's, and is the majority shareholder of Pilgrim's Pride Corporation.
Read more on JBS →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
